PWM
NMTR

Prentice Wealth Management’s 9 Meters Biopharma NMTR Stock Holding History

Prentice Wealth Management’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,301
Closed -$10K – 98
2022
Q3 		$10K Buy
+2,301
New +$11.4K 0.01% 89
2022
Q2 		– Sell
-1,976
Closed -$23K – 199
2022
Q1 		$23K Buy
1,976
+226
+13% +$3.09K 0.01% 99
2021
Q4 		$34K Buy
1,750
+300
+21% +$6.71K 0.02% 101
2021
Q3 		$38K Buy
1,450
+540
+59% +$12.7K 0.02% 187
2021
Q2 		$20K Buy
910
+290
+47% +$7.12K 0.01% 216
2021
Q1 		$15K Buy
+620
New +$19.1K 0.01% 229

Other funds holding NMTR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ODFS
O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return

Prentice Wealth Management's NMTR Position: Q4 2022 in Review

Prentice Wealth Management sold out of 9 Meters Biopharma (NMTR) in Q4 2022, closing a stake of 2,301 shares — an estimated $10K sold.

Prentice Wealth Management first reported a position in NMTR in Q1 2021 and held it in 6 quarters. The position peaked at $38K in Q3 2021. 42 funds tracked by Wall St. Rank hold NMTR as of Q4 2022.

  • Prentice Wealth Management reported no remaining 9 Meters Biopharma position as of Q4 2022 after selling out during the quarter.
  • Prentice Wealth Management sold 2,301 9 Meters Biopharma shares in Q4 2022, an estimated $10K.
  • Prentice Wealth Management first reported a position in 9 Meters Biopharma in Q1 2021 and held it in 6 quarters.
  • Prentice Wealth Management's 9 Meters Biopharma position peaked at $38K in Q3 2021.
  • 42 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2022.

Based on Prentice Wealth Management's 13F filing for Q4 2022, filed 18 Jan 2023.